Approach

APPROACH

Barinthus Biotherapeutics is advancing the next generation of antigen-specific immunotherapies for treating autoimmunity, chronic infectious diseases and cancer.

Antigen-specific immunotherapies leverage the power of the immune system’s T cells.

T cells are key to our body’s ability to identify and respond to threats through recognition of antigens. Disease occurs when the T cell response is either inappropriate, as occurs in autoimmunity, or inadequate, as often occurs in chronic viral infections or cancer.

To help patients gain control over their disease, Barinthus Biotherapeutics is developing antigen-specific immunotherapies. Key aspects of these therapies are that they are designed to be specific to the disease and precisely engineered with the aim of either guiding a patient’s T cells to become regulatory T (Treg) cells that promote immune tolerance or effector T (Teff) cells that can be directed to eliminate virally infected or cancer cells.

Our approach has potential in multiple therapeutic areas.

Barinthus Biotherapeutics has built a suite of proprietary technology platforms that aim to guide T cell immunity to address diverse disease processes ranging from autoimmunity to chronic viral infections.

Tolerance Immunotherapies

  • Inflammatory diseases including autoimmunity, allergies, and transplant rejection can occur due to an imbalance in the immune system with Teff cells overwhelming Treg cells that promote tolerance.
  • Barinthus Bio aims to restore balance with antigen-specific tolerance immunotherapies based on our SNAP-TI technology platform that directly addresses disease pathology and are potentially curative.

Anti-Viral Immunotherapies

  • Chronic viral infections can occur when the immune system’s Teff cell response is inadequate and becomes exhausted.
  • To address this challenge, Barinthus Bio is developing anti-viral immunotherapies based on vectored platforms that aim to recruit and expand Teff cells to the numbers and functionality needed for clearing chronic viral infections.

Cancer Immunotherapies

  • Cancers can arise when the immune system’s Teff cell response is inadequate or unable to recognize cancer cells.
  • To address this challenge, Barinthus Bio is developing cancer immunotherapies based on vectored platforms that aim to induce unprecedented high magnitude and quality of Teff cells that are needed to fight advanced cancers.